January MIMS Update

Some of the recent changes to the medicines landscape, with new products, indications and safety-related changes New Products Amivantamab (Rybrevant) is a low-fucose, fully-human IgG1-based bispecific antibody that binds to the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal epidermal transition (MET) receptor. It disrupts EGFR and MET signalling functions through blocking ligand